An AE with an onset on or within 48 hours after a dose of study drug, or an event that worsened in intensity within 48 hours of a dose of study drug was considered a treatment-emergent adverse event (TEAE).

A summary of serious adverse events (SAEs) and other non-serious adverse events (AEs), regardless of causality, were reported in the Reported Adverse Events module.

All randomized participants who received at least one dose of study drug and were analyzed by randomized treatment regimen, as pre-specified in the SAP.

Participants who discontinued due to adverse events were reported in this outcome measure.

All randomized participants who received at least one dose of study drug and were analyzed by randomized treatment regimen, as pre-specified in the SAP.

Pain relief at 2 hours post-dose was defined as having a pain intensity of none or mild at that time point. The 5-Face Pain Scale is a single-item, self-report tool assessing pain intensity along a single domain. Participants select one face from five options to represent their current pain level; no score aggregation or calculation is performed- the selected face directly represents the pain intensity score. The five faces correspond to: Face 1= none, Face 2= mild, Faces 3-4= moderate (both faces represent moderate pain as defined by this scale, with Face 3 reflecting lower-moderate and Face 4 reflecting upper-moderate intensity) and Face 5= severe. The scale ranges from a minimum value of 1 (no pain) to a maximum value of 5 (severe pain); higher scores indicate worse outcome. Participants with a reduction in baseline pain from moderate (Faces 3 or 4) or severe (Face 5) to no pain (Face 1) at 2 hours post-dose were considered to have achieved pain freedom.

Evaluable population by treated migraine attack included all migraine attacks treated with study drug among participants who were randomized and received at least one dose of study drug. Each treated migraine attack was analyzed according to the exposure of lasmiditan. As pre-specified in the SAP, efficacy data were censored after rescue medication use; missing data were handled using observed data, with non-responder imputation.

Pain relief at 2 hours post-dose was defined as having a pain intensity of none or mild at that time point. The 5-Face Pain Scale is a single-item, self-report tool assessing pain intensity along a single domain. Participants select one face from five options to represent their current pain level; no score aggregation or calculation is performed- the selected face directly represents the pain intensity score. The five faces correspond to: Face 1= none, Face 2= mild, Faces 3-4= moderate (both faces represent moderate pain as defined by this scale, with Face 3 reflecting lower-moderate and Face 4 reflecting upper-moderate intensity) and Face 5= severe. The scale ranges from a minimum value of 1 (no pain) to a maximum value of 5 (severe pain); higher scores indicate worse outcome. Participants with reduction from baseline moderate (Faces 3 or 4) or severe (Face 5) to mild or none (Face 1 or 2), or those reported as asleep at 2 hours post-dose were considered to have achieved pain relief.

Evaluable population by treated migraine attack included all migraine attacks treated with study drug among participants who were randomized and received at least one dose of study drug. Each treated migraine attack was analyzed according to the exposure of lasmiditan. As pre-specified in the SAP, efficacy data were censored after rescue medication use; missing data were handled using observed data, with non-responder imputation.

Participants identified one pre-specified most bothersome symptom (MBS) prior to each migraine dose from three options (nausea, photophobia, or phonophobia). The same pre-selected MBS was assessed at baseline (pre-dose) and at 2 hours post-dose using a binary scale recorded via electronic diary (e-Diary), where "Yes" = MBS present and "No" = MBS absent.

MBS freedom was defined as a change from MBS present ("Yes") at baseline to MBS absent ("No") at 2 hours post-dose. A response of "No" at 2 hours post-dose represents a favorable outcome. Only migraine attacks in which the MBS was reported as present at baseline were included in the analysis. No aggregation, transformation, or total score calculation was performed, as this is a single-item dichotomous assessment per attack.

Evaluable population by treated migraine attack included all migraine attacks treated with study drug among participants who were randomized and received at least one dose of study drug. Each treated migraine attack was analyzed according to the exposure of lasmiditan. As pre-specified in the SAP, efficacy data were censored after rescue medication use; missing data were handled using observed data, with non-responder imputation.